For those at one end of the spectrum- life extension seekers (including some deep-pocketed Silicon Valley investors)-the answer is “yes.” They believe biotechnology will lengthen human life spans to range anywhere from 1,000 years to forever.
Regarding this, what biotech company did Jeff Bezos just invest in?
Mindstrong Health. Bezos Expeditions, along with Decheng Capital and other investors, kicked in $15 million to Mindstrong Health’s Series B funding stage in 2018. The company’s mission is to transform “mental health through innovations in virtual care, data measurement, and data science.”
Additionally, what is the new anti-aging drug?
The drug rapamycin recently became one of the most promising anti-ageing substances and shows positive effects on health in old age. “Rapamycin turns down the TOR signalling pathway that regulates a wide spectrum of basic cellular activities such as energy, nutritional and stress status.
Is it possible to reverse aging?
What may come as a surprise to many, the answer is yes! In the last few years, scientists have shown that it’s actually possible to partially reverse aging: they succeeded in making old organisms younger.
A new study suggests that stopping or even reversing the aging process is impossible. In a collaborative effort from scientists worldwide, including experts from the University of Oxford, it was concluded that aging is inevitable due to biological constraints, The Guardian reported.
Buffet’s Berkshire Hathaway bought 648,447 shares of the Big Biotech at a combined worth of $192.4 million near the end of 2019, the investment shop disclosed in a recent securities filing. The equity buildup came as a surprise given that the Oracle of Omaha isn’t often associated with biotech investments.
Exactly one year ago, BioSpace reported that Buffett’s Berkshire Hathaway Inc. was investing heavily in four pharmaceutical companies: Pfizer, Bristol-Myers Squibb, AbbVie, and Merck & Co.
Jeff Bezos reportedly invests in Altos Labs, the latest startup trying to extend human life. Amazon ex-CEO Jeff Bezos has been looking to space for humanity’s future. But the world’s richest man is also trying to extend humanity’s lifespan here on Earth, according to a report in MIT’s Technology Review.
Unity Biotechnology is the leader in the senolytics industry in terms of clinical development. No other company even has a firm date to enter the clinic while Unity is already trialling their 2nd drug.
Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumor (PEComa).